Polarean Imaging plc the medical imaging technology company, announces that the FDA has granted approval for its drug device combination product, Xenoview
Xenon Pharmaceuticals Inc. provided an update on its two ongoing collaborations focused on identifying and developing novel pain targets and...
Xenon Pharmaceuticals Inc. provided regulatory updates on its proprietary pediatric neurology program, XEN 496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).
Radioiodine thyroid therapy is indicated in adults and children for: • Hyperthyroidism: Treatment of Graves' disease, toxic multinodular goitre or autonomous nodules. • Treatment of papillary and follicular thyroid carcinoma including metastatic disease. Sodium iodide ( 131 I) therapy is often combined with surgical intervention and with antithyroid medicinal products.